Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
10,006
datasets available to search
ShareScore release 0.9.0
Dataset results
10,006 results for “randomness”
Mosaic image of Crab region extracted from a sample of 50 randomly selected ScWs, together with the display of the catalog of detectedsources.
<p><a href="https://www.astro.unige.ch/cdci/astrooda_?src_name=Crab&RA=83.633080&DEC=22.014500&T1=2003-03-15T23:27:40.0&T2=2018-03-16T00:03:15.0&T_format=isot&instrument=isgri&osa_version=OSA10.2&radius=15&use_scws=no&E1_keV=20&E2_keV=40&query_type=Real&detection_threshold=7.5&product_type=isgri_image">www.astro.unige.ch/cdci/astrooda_?src_name=Crab&RA=83.633080&DEC=22.014500&T1=2003-03-15T23:27:40.0&T2=2018-03-16T00:03:15.0&T_format=isot&instrument=isgri&osa_version=OSA10.2&radius=15&use_scws=no&E1_keV=20&E2_keV=40&query_type=Real&detection_threshold=7.5&product_type=isgri_image</a></p>
Crab long-term (15 year time span) lightcurve extracted froma sample of 50 randomly selected ScWs in 30-100 keV band, usingOSA10.2.
<p><a href="https://www.astro.unige.ch/cdci/astrooda_?src_name=Crab&RA=83.633080&DEC=22.014500&E1_keV=30&E2_keV=100&T1=2003-03-15T23:27:40.0&T2=2018-03-16T00:03:15.0&T_format=isot&catalog_selected_objects=1,2,3,4&detection_threshold=7.5&instrument=isgri&osa_version=OSA10.2&product_type=isgri_lc&time_bin=10000&time_bin_format=sec&query_status=ready&query_type=Real&radius=15&use_scws=no&selected_catalog=%7B%22cat_column_descr%22:%5B%5B%22meta_ID%22,%22%3Ci8%22%5D,%5B%22src_names%22,%22%7CS18%22%5D,%5B%22significance%22,%22%3Ef4%22%5D,%5B%22ra%22,%22%3Ef4%22%5D,%5B%22dec%22,%22%3Ef4%22%5D,%5B%22NEW_SOURCE%22,%22%3Ei2%22%5D,%5B%22ISGRI_FLAG%22,%22%3Ci8%22%5D,%5B%22FLAG%22,%22%3Ci8%22%5D,%5B%22ERR_RAD%22,%22%3Cf8%22%5D%5D,%22cat_column_list%22:%5B%5B1,2,3,4%5D,%5B%221A+0535%2B262%22,%224U+0517%2B17%22,%22Crab%22,%22H+0614%2B091%22%5D,%5B116.77162170410156,7.909553527832031,1232.6466064453125,8.148767471313477%5D,%5B84.72620391845703,77.66708374023438,83.63129425048828,94.25425720214844%5D,%5B26.314136505126953,16.48775863647461,22.01542854309082,9.165886878967285%5D,%5B-32768,-32768,-32768,-32768%5D,%5B2,2,2,2%5D,%5B0,0,0,0%5D,%5B0.0002800000074785203,0.0002800000074785203,0.0002800000074785203,0.0002800000074785203%5D%5D,%22cat_column_names%22:%5B%22meta_ID%22,%22src_names%22,%22significance%22,%22ra%22,%22dec%22,%22NEW_SOURCE%22,%22ISGRI_FLAG%22,%22FLAG%22,%22ERR_RAD%22%5D,%22cat_coord_units%22:%22deg%22,%22cat_frame%22:%22fk5%22,%22cat_lat_name%22:%22dec%22,%22cat_lon_name%22:%22ra%22%7D">https://www.astro.unige.ch/cdci/astrooda_?src_name=Crab&RA=83.633080&DEC=22.014500&E1_keV=30&E2_keV=100&T1=2003-03-15T23:27:40.0&T2=2018-03-16T00:03:15.0&T_format=isot&catalog_selected_objects=1,2,3,4&detection_threshold=7.5&instrument=isgri&osa_version=OSA10.2&product_type=isgri_lc&time_bin=10000&time_bin_format=sec&query_status=ready&query_type=Real&radius=15&use_scws=no&selected_catalog={%22cat_column_descr%22:[[%22meta_ID%22,%22%3Ci8%22],[%22src_names%22,%22|S18%22],[%22significance%22,%22%3Ef4%22],[%22ra%22,%22%3Ef4%22],[%22dec%22,%22%3Ef4%22],[%22NEW_SOURCE%22,%22%3Ei2%22],[%22ISGRI_FLAG%22,%22%3Ci8%22],[%22FLAG%22,%22%3Ci8%22],[%22ERR_RAD%22,%22%3Cf8%22]],%22cat_column_list%22:[[1,2,3,4],[%221A+0535%2B262%22,%224U+0517%2B17%22,%22Crab%22,%22H+0614%2B091%22],[116.77162170410156,7.909553527832031,1232.6466064453125,8.148767471313477],[84.72620391845703,77.66708374023438,83.63129425048828,94.25425720214844],[26.314136505126953,16.48775863647461,22.01542854309082,9.165886878967285],[-32768,-32768,-32768,-32768],[2,2,2,2],[0,0,0,0],[0.0002800000074785203,0.0002800000074785203,0.0002800000074785203,0.0002800000074785203]],%22cat_column_names%22:[%22meta_ID%22,%22src_names%22,%22significance%22,%22ra%22,%22dec%22,%22NEW_SOURCE%22,%22ISGRI_FLAG%22,%22FLAG%22,%22ERR_RAD%22],%22cat_coord_units%22:%22deg%22,%22cat_frame%22:%22fk5%22,%22cat_lat_name%22:%22dec%22,%22cat_lon_name%22:%22ra%22}</a></p>
Reference set of random studies from Embase
<p>These are two datasets in a simple Excel file, and separated as two .csv files. They contain a random set of Embase studies, that can be used for projects around search strategy development.</p> <p>1. A random selection of 1000 articles from Embase, letters removed. Two assessors indicated whether a study was a diagnostic accuracy study or not. The scores of the assessors and the final decision are included in the dataset, as well as comments. Also, for each study has been indicated whether they are labelled as "Diagnostisc Test Accuracy Study" by Embase.</p> <p>2. A random selection of 1223 articles from Embase, letters removed and limited to human-only studies. Two assessors indicated whether a study was a diagnostic accuracy study or not. The scores of the assessors and the final decision are included in the dataset, as well as comments. Also, for each study has been indicated whether they are labelled as "Diagnostisc Test Accuracy Study", "Diagnostic Test Accuracy" or as "Sensitivity and Specificity" by Embase.</p>
Electron number density and DM density along random lines of sight from the EAGLE simulation
<p>Here we present the electron number density and the dark matter (DM) density along random lines of sight (LOS) extracted from the EAGLE simulation. The data sets contain two types of LOS - with the cross sections <span class="math-tex">\(25\times20\text{ ckpc}^2\)</span> and <span class="math-tex">\(250\times25\text{ ckpc}^2\)</span>(ckpc is comoving kpc). The datasets contain snapshots of the electron number density at <span class="math-tex">\(23\)</span> different redshift points <span class="math-tex">\(z_i\)</span>, <span class="math-tex">\(0\le z_i \le 6\)</span> and <span class="math-tex">\(37\)</span> snapshots of the DM density for <span class="math-tex">\(0\le z_i\le125\)</span>. At each <span class="math-tex">\(z_i\)</span> there are data for <span class="math-tex">\(100\)</span> random LOS (of each type), having comoving length <span class="math-tex">\(100\text{ cMpc}\)</span> and containing <span class="math-tex">\(5000\)</span> data points each.</p> <p>In addition to the raw data we provide a Wolfram Mathematica notebook <strong>LOS.nb</strong>, that gives examples of usage, namely:</p> <ul> <li>Construction the continuous lines of sight for electron number density or DM density;</li> <li>Calculation the resonant conversion probability between dark photon and usual photon along the LOS;</li> <li>Production of the signal in the model where DM decays into dark photons that are later converted into usual photons.</li> </ul> <p>The details of extraction procedure and LOS properties, as well as physical result in the example models are discussed in the paper <a href="https://arxiv.org/abs/2003.10465">[2003.10465]</a>. Please cite this paper if you use data published here.</p> <p><em>To get started download all files in one folder and run the Mathematica notebook.</em></p> <p>Changes in v2: Bug with names of data files was corrected. Minor changes in LOS.nb</p>
Data from: Risky behaviors and Parkinson's disease: a Mendelian randomization study
Objective: To examine causal associations between risky behavior phenotypes on Parkinson's disease using a Mendelian randomization approach. Methods: We used two-sample Mendelian randomization to generate unconfounded estimates using summary statistics from two independent, large meta-analyses of genome-wide association studies on risk taking behaviors (n=370,771-939,908) and Parkinson's disease (cases: n=9581, controls: n = 33,245). We used inverse variance weighted as the main method for judging causality. Results: Our results support a strong protective association between the tendency to smoke and Parkinson's disease (OR=0.714 per log odds of ever smoking; 95% CI=0.568-0.897; p-value=0.0041; Cochran Q test; p-value=0.238; I2 index=6.3%). Furthermore, we observed risk association trends between automobile speed propensity as well as the number of sexual partners and Parkinson's disease after removal of overlapping loci with other risky traits (OR=1.986 for each standard deviation increase in normalized automobile speed propensity; 95% CI=1.215-3.243; p-value=0.0066, OR=1.635 for each standard deviation increase in number of sexual partners; 95% CI=1.165-2.293; p-value=0.0049). Conclusion: These findings provide support for a causal relationship between general risk tolerance and Parkinson's disease and may provide new insights in the pathogenic mechanisms leading to the development of Parkinson's disease.
MCMC Chains and Maximum Likelihood Parameters for a Random Walk Model of Dark Matter Halo Spins
<p>MCMC chains and the maximum likelihood model parameter file associated with the random walk dark matter halo spin model of Benson, Behrens, & Lu (2020; https://arxiv.org/abs/2001.09208). See the README file for details.</p>
Physical Exercise in Patients with Subacute Stroke (PHYS-STROKE): safety analyses of six-month follow-up of a randomized clinical trial
<p>This dataset supports the findings of the published article 'Physical Exercise in Patients with Subacute Stroke (PHYS-STROKE): safety analyses of six-month follow-up of a randomized clinical trial'.</p> <p>Data includes the raw data, and an analysis script for the main study outcomes.</p>
The code and mathematical derivation associated with "The role of random vorticity stretching in an idealized tropical depression genesis problem"
<p>1. The "SWE.rar" is the shallow water model (SWE).</p> <p>2. The "postprocess.rar" is the postprocessing code, include plottings and parameter estimation.</p> <p>3. The hand-written mathematical derivation of this paper is made with ONENOTE. It can be found at:</p> <p>https://office365stanford-my.sharepoint.com/:o:/g/personal/haofu_stanford_edu/El0w-3bEQABDnEVScJH6CK8BYVtxF33RzjmeZTbgaPyU-g?e=wae0Ra</p> <p>4. If there is any question or difficulty in downloading, please contact Hao Fu: haofu@stanford.edu</p>
Generation of stable mammalian cell lines for the expression of proteins related to COVID-19 through random integration
<p>Scientists centred around University of Oxford came together in the current COVID-19 pandemic to contribute to relevant studies collaboratively. Researchers with no prior experience in virology studies, myself included, had volunteered our time to contribute whichever way we can based on our field of expertise. The Biotech team of SGC Oxford, headed by Nicola Burgess-Brown had taken up the role of producing proteins used in serological assays, basic research to understand COVID-19 pathophysiology and hunt for treatment compounds. The initial production of these proteins was based on transient transfection of expression construct DNA into mammalian cells. This approach was laborious and consumed large amounts of plasmid DNA. Therefore, I volunteered to generate stable expression cell lines that will negate the constant need for transfection.</p> <p>I aimed to stably integrate the expression constructs into the genome of Expi293F human cells commonly used in large scale protein production. The expression constructs carried neomycin marker for selection in mammalian cells. Toxicity to the cells is not a concern in this case because the expressed proteins are secreted into the medium and do not build up in the cells. The expression constructs are randomly integrated into the genome mainly via non-homologous end-joining (NHEJ). An advantage of this approach is that molecular sub-cloning is not necessary.</p> <p>In order to maximise the rate of correct integration of the expression constructs, restriction digestion was performed to cut once between the expression cassette and antibiotic resistance cassette (refer to cartoon in Figure 1). Without this step, the construct DNA will be broken at a random position during the integration step, potentially disrupting the expression cassette. I have also tested the effect of actively creating double strand breaks (DSBs) in the genome of the cells on the integration efficiency. More DSBs in the genome might increase the incidence of NHEJ and integration of our constructs. This was achieved by co-transfection of AAVS1 CRISPR/eSpCas9(1.1) construct (refer to cartoon in Figure 1). The eSpCas9(1.1)_No_FLAG_AAVS1_T2 construct was a gift from Yannick Doyon (Addgene plasmid # 79888 ; http://n2t.net/addgene:79888 ; RRID:Addgene_79888)</p> <p> </p> <p>Please refer to my SGC opennotebook post for my other research work unrelated to the pandemic.</p> <p>https://openlabnotebooks.org/generation-of-stable-mammalian-cell-lines-for-the-expression-of-proteins-related-to-covid-19-through-random-integration/</p>
The performance of permutations and exponential random graph models when analysing animal networks (R code and data)
<p>Social network analysis is a suite of approaches for exploring relational data. Two approaches commonly used to analyse animal social network data are permutation-based tests of significance and exponential random graph models. However, the performance of these approaches when analysing different types of network data has not been simultaneously evaluated. Here we test both approaches to determine their performance when analysing a range of biologically realistic simulated animal social networks. We examined the false positive and false negative error rate of an effect of a two-level explanatory variable (e.g. sex) on the number and combined strength of an individual's network connections. We measured error rates for two types of simulated data collection methods in a range of network structures, and with/without a confounding effect and missing observations. Both methods performed consistently well in networks of dyadic interactions, and worse on networks constructed using observations of individuals in groups. Exponential random graph models had a marginally lower rate of false positives than permutations in most cases. Phenotypic assortativity had a large influence on the false positive rate, and a smaller effect on the false negative rate for both methods in all network types. Aspects of within- and between-group network structure influenced error rates, but not to the same extent. In grouping-event based networks, increased sampling effort marginally decreased rates of false negatives, but increased rates of false positives for both analysis methods. These results provide guidelines for biologists analysing and interpreting their own network data using these methods.</p>
Parathyroid hormone and bone mineral density: a Mendelian randomization study
<p><b>Purpose:</b> Accumulating evidence implicates parathyroid hormone (PTH) in the development of osteoporosis. However, the causal effect of PTH on bone mineral density (BMD) remains unclear. Thus, this study aimed at exploring the association between the concentrations of serum PTH and BMD.</p> <p><b>Methods:</b> The<b> </b>instrumental variables for PTH were selected from a large-scale genome-wide association study (GWAS) [n = 29,155]. Outcomes included BMD of forearm (FA) [n = 8143], femoral neck (FN) [n = 33,297], lumbar spine (LS) [n = 32,735], heel (HL) [n = 394,929] and risk of fractures in these bones (n = 361,194). Furthermore, the BMD of five different age groups; 15 or less [n = 11,807], 15-30 [4180], 30-45 [10,062], 45-60 [18,805] and 60 or more [22,504] were extracted from a GWAS meta-analysis study. The analyses were performed using the two-sample Mendelian randomization (MR) method.</p> <p><b>Results: </b>MR analysis revealed that the level of serum PTH were inversely associated with BMD of FA (95% CI: -0.763 to -0.016), FN (95% CI: -0.669 to -0.304) and LS (95% CI: -0.667 to -0.243). A causal relationship between serum PTH levels and BMD was observed in individuals aged 30-45 (95% CI: -0.888 to -0.166), 45-60 (95% CI: -0.758 to -0.232) and over 60 years (95% CI: -0.649 to -0.163).</p> <p><b>Main conclusions: </b>This study demonstrated that the concentrations of serum PTH is inversely associated with BMD of several bones. Further analysis revealed a site and age-specific correlations between serum PTH levels and BMD, which implies that the levels of serum PTH contribute to the development of osteoporosis.</p>
The effects of LED-mediated photobiomodulation vs no photobiomodulation on extraction space closure in adolescents and young adult patients: A split-mouth, randomized controlled trial.
<p>The aim of this split-mouth trial was is to examine the effects of light emitting diode (LED)-mediated photobiomodulation (PBM) compared to no photobiomodulation on maxillary canine distalization.</p> <p>The dataset is openly provided upon acceptance for publication.</p>
MCMC Chains and Maximum Likelihood Parameters for a Random Walk Model of Dark Matter Halo Concentrations
<p>MCMC chains and the maximum likelihood model parameter file associated with the random walk dark matter halo concentration model of Johnson, Benson, & Grin (2020; https://arxiv.org/abs/2006.15231). See the README file for details.</p>
CARE-CF-1 Clinical trial data: An exploratory, randomized, double-blind, placebo-controlled 6-arm clinical trial examining cysteamine as an adjunct therapy for the treatment of pulmonary exacerbations of cystic fibrosis
<p><em>Background:</em> Emerging data suggests a possible role for cysteamine as an adjunct treatment for pulmonary exacerbations of cystic fibrosis (CF) that continue to be a major clinical challenge. There are no studies investigating the use of cysteamine in pulmonary exacerbations of CF. This exploratory randomized clinical trial was conducted to answer the question: In future pivotal trials of cysteamine as an adjunct treatment in pulmonary exacerbations of CF, which candidate cysteamine dosing regimens should be tested and which are the most appropriate, clinically meaningful outcome measures to employ as endpoints?</p> <p><em>Methods and findings: </em>Multicentre double-blind randomized clinical trial. Adults experiencing a pulmonary exacerbation of CF being treated with standard care that included aminoglycoside therapy were randomized equally to a concomitant 14-day course of placebo, or one of 5 dosing regimens of cysteamine. Outcomes were recorded on days 0, 7, 14 and 21 and included sputum bacterial load and the patient reported outcome measures (PROMs): Chronic Respiratory Infection Symptom Score (CRISS), the Cystic Fibrosis Questionnaire–Revised (CFQ-R); FEV1, blood leukocyte count, and inflammatory markers. Eighty nine participants in fifteen US and EU centres were randomized, 78 completed the 14-day treatment period. Cysteamine had no significant effect on sputum bacterial load, however technical difficulties limited interpretation. The most consistent findings were for cysteamine 450mg twice daily that had effects additional to that observed with placebo, with improved symptoms, CRISS additional 9.85 points (95% CI 0.02, 19.7) p=0.05, reduced blood leukocyte count by 2.46x109 /l (95% CI 0.11, 4.80), p=0.041 and reduced CRP by geometric mean 2.57 nmol/l (95% CI 0.15, 0.99), p=0.049.</p> <p><em>Conclusion:</em> In this exploratory study cysteamine appeared to be safe and well-tolerated. Future pivotal trials investigating the utility of cysteamine in pulmonary exacerbations of CF need to include the cysteamine 450mg doses and CRISS and blood leukocyte count as outcome measures.</p>
Heat shock improves random spore analysis in diverse strains of Saccharomyces cerevisiae
<p>Random spore analysis (RSA) is a classic method in yeast genetics that allows high-throughput purification of recombinant haploid spores following specific crosses. RSA typically involves a number of steps to induce sporulation, purge vegetative cells that fail to sporulate, and disrupt the ascus walls of sporulated cells to release haploid spores. These steps generally require expensive chemicals and/or enzymes that kill diploid cells but have few effects on spores. In the fission yeast <em>Schizosaccharomcyes pombe</em>, heat shock has been reported as an effective addition to RSA protocols, but to our knowledge heat shock not been used for this purpose in the budding yeast <em>Saccharomyces cerevisiae</em>. Here, we evaluate the effects of heat shock on vegetative and sporulated cultures of four diverse yeast strains: a European wine strain (DBVPG6765), a Japanese sake strain (Y12), a West African palm wine strain (DBVPG6044) and a North American strain isolated from the soil beneath an oak tree (YPS128). We characterize this phenotype under multiple combinations of temperature and incubation time, and find specific conditions that lead to the exclusion of vegetative cells and an enrichment in spores, which differ by strain. We also collected genome sequence data from a recombinant population that experienced multiple rounds of RSA, including one round with a heat shock treatment. These data suggest that when incorporated into an RSA protocol, heat shock leads to increased genetic diversity among the cells that survive and mate. Ultimately, our work provides evidence that short heat treatments can improve existing RSA protocols, though in a strain-specific manner. This result informs applications of high-throughput RSA protocols, such as QTL mapping and experimental evolution research.</p>
Data from: Cell therapy for chronic TBI: interim analysis of the randomized, controlled, double-blind STEMTRA trial
<p><b>Objective:</b> To determine if chronic motor deficits secondary to traumatic brain injury (TBI) can be improved by implantation of allogeneic modified bone marrow-derived mesenchymal stromal/stem cells (SB623).</p> <p><b>Methods:</b> This 6-month interim analysis of the 1-year double-blind, randomized, surgical sham-controlled, Phase 2 STEMTRA trial (NCT02416492) evaluated safety and efficacy of the stereotactic intracranial implantation of SB623 in patients with stable chronic motor deficits secondary to TBI. Patients in this multi-center trial (N=63) underwent randomization in a 1:1:1:1 ratio to 2.5x10<sup>6</sup>, 5.0x10<sup>6</sup>, 10x10<sup>6</sup> SB623 cells or control. Safety was assessed in patients who underwent surgery (N=61), and efficacy in the modified intent-to-treat population of randomized patients who underwent surgery (N=61; SB623=46, control=15).</p> <p><b>Results:</b> The primary efficacy endpoint of significant improvement from baseline of Fugl-Meyer Motor Scale score at 6 months for SB623-treated patients was achieved. SB623-treated patients improved by (LS mean [SE]) +8.3 (1.4) versus +2.3 (2.5) for control at 6 months, the LS mean difference was 6.0 (95% CI: 0.3-11.8); P=0.040. Secondary efficacy endpoints improved from baseline, but were not statistically significant versus control at 6 months. There were no dose-limiting toxicities or deaths, and 100% of SB623-treated patients experienced treatment-emergent adverse events versus 93.3% of control patients (P=0.25).</p> <p><b>Conclusions:</b> SB623 cell implantation appeared to be safe and well tolerated, and patients implanted with SB623 experienced significant improvement from baseline motor status at 6 months compared to controls.</p> <p><b>Classification of Evidence:</b> This study provides Class I evidence that implantation of SB623 was well tolerated and associated with improvement in motor status.</p>
Ivermectin as a potential treatment for mild to moderate COVID-19 – A double blind randomized placebo-controlled trial
<p><b>Objective:</b> Ivermectin has been suggested as a treatment for COVID-19.This randomised control trial was conducted to test the efficacy of Ivermectin in the treatment of mild and moderate COVID-19.</p> <p><b>Design:</b> Parallel, double blind, randomised, placebo controlled trial</p> <p><b>Setting:</b> A tertiary care dedicated COVID-19 hospital in Bihar, India</p> <p><b>Participants:</b> Adult patients (> 18 years) admitted with mild to moderate COVID 19 disease (saturation > 90% on room air, respiratory rate < 30 and no features of shock) with no contraindications to ivermectin and willing to participate in the study</p> <p><b>Intervention:</b> Patients in the intervention arm were given ivermectin 12 mg on day 1 and day 2 of admission. Patients in the placebo arm were given identical looking placebo tablets. Rest of the treatment was continued as per the existing protocol and the clinical judgment of the treating teams.</p> <p><b>Outcome Measures:</b> The primary outcome measure was a negative RT-PCR test for SARS-CoV-2 on day 6 of admission. The secondary outcome measures were symptom status on day 6, discharge status on day 10, admission to ICU, need for invasive mechanical ventilation and in-hospital mortality.</p> <p><b>Results:</b> A total of 115 patients were enrolled for the study of which 112 were included in the final analysis. Of them, 55 were randomised to the intervention arm while 57 were randomised to the placebo arm. There was no significant difference in the baseline characteristics of the two arms. There was no significant difference in the primary outcome, i.e. negative RT-PCR status on day 6 between the two groups. Similarly, there was no significant difference between the two groups in most of the secondary outcome measures, viz. symptom status on day 6, discharge status on day 10, admission to ICU, and need for invasive mechanical ventilation. However, while there was no in-hospital mortality in the intervention arm, there were 4 deaths in the placebo arm. As a result, all patients in the intervention arm (n=56) were successfully discharged as compared to 93.1% (n=54/58) in the placebo arm (RR 1.1, 95% CI 1.0 to 1.2, p=0.019).</p> <p><b>Conclusion:</b> There was no difference in the primary outcome i.e. negative RT-PCR status on day 6 of admission with the use of ivermectin. However, a significantly higher proportion of patients were discharged alive from the hospital when they received ivermectin.</p>
Staggering Sugammadex for Reduction of Postoperative Complications: A Randomized Controlled Trial
<p><strong>Background:</strong> We investigated if staggering sugammadex would reduce postoperative complications(with special regards to cough), compared to single dose of sugammadex or standard neostigmine in patients undergoing thyroidectomy surgery.</p> <p><strong>Methods</strong>: A 36 adult patients aged 21-60 years old, ASA I and II undergoing thyroidectomy surgery, were randomized into 3 groups; (S group) that received 2 mg/kg sugammadex as single bolus, (SS group) that received sugammadex 2 mg/kg in a staggered dose of 1 mg/kg prior to extubation and another 1 mg/kg immediately after extubation and (N group) that received 0.05 mg/kg neostigmine combined with 0.02 mg/kg atropine.</p> <p><strong>Results</strong>: Cough was absent in (SS) group. The percent of cough was 33% in S group and about 67 % in N group.Patients of (SS) and (S) groups had significant shorter recovery time and extubation time. Patients of (N) group showed significant increase in HR and SBP at 5 min after reversal compared to both (SS) and (S) groups, but no significant difference in DBP between all groups. There was no significant difference between all groups regarding postoperative complications other than cough.</p> <p><strong>Conclusion: </strong>Staggered sugammadex reduces significantly risks for cough on emergence when compared to 2mg single bolus sugammadex .In addition, staggered sugammadex-as well as bolus sugammadex-has better recovery and more stable hemodynamics when compared to neostigmine.</p>
Searching for evidence of algorithmic randomness and incomputability in the output of quantum random number generators
<p>This upload contains the data and code used in the following paper:</p> <p>J. T. Kavulich, B. P. Van Deren, and M. Schlosshauer, “Searching for evidence of algorithmic randomness and incomputability in the output of quantum random number generators,” <em>Phys. Lett. A</em> 388, 127032 (2021), <a href="https://doi.org/10.1016/j.physleta.2020.127032">doi.org/10.1016/j.physleta.2020.127032</a></p> <p>The contents of the data set are as follows:</p> <p>1) Random strings for two QRNGs and four PRNGs. For each RNG, a zip archive provides 100 strings containing 25 x 2<sup>26</sup> = 1,677,721,600 bits each.</p> <p>2) C++ code for the Chaitin–Schwartz–Solovay–Strassen (CSSS) and Borel-normality tests (code.zip, 13 KB).</p> <p>The bulk of this code is not ours, but was written and made publicly available at <a href="https://www.cs.auckland.ac.nz/research/groups/CDMTCS/export/80_random_seqs">this link</a> by the authors of the following paper:</p> <p>A. A. Abbott, C. S. Calude, M. J. Dinneen, and N. Huang, <em>Phys. Scri.</em> 94 (2019) 045103, <a href="https://doi.org/10.1088/1402-4896/aaf36a">doi:10.1088/1402-4896/aaf36a</a></p> <p>We have made just a few small modifications to their original code:</p> <ul> <li>For the CSSS tests, a text file containing the Carmichael numbers (for tests 1–3) and odd composites up to 100 (for test 4) is read in and used to perform the tests. (Note: The set of Carmichael numbers used in the tests was generously provided to us by R. G. E. Pinch. Reference: R. G. E. Pinch, The Carmichael numbers up to 10<sup>21</sup>, in: A.-M. Ernvall-Hytönen (Ed.), Proceedings of Conference on Algorithmic Number Theory, Vol. 46, Turku Centre for Computer Science, Turku, Finland, 2007, pp. 129–131.)</li> <li>We combined the first and second CSSS tests into a single program.</li> <li>We reformatted the display of the output, and included a VERBOSE flag for additional status output.</li> </ul> <p>3) Results from CSSS and Borel-normality tests in Python format (results.zip, 22 KB). This archive also contains a Python script (analyze.py) that reads the result files, carries out the statistical analysis, and displays the plots.</p>
Data from: Daridorexant, a new dual orexin receptor antagonist in elderly subjects with insomnia disorder: a randomized clinical trial
<p><b>Objective:</b> To assess the dose-response of daridorexant, a new dual orexin receptor antagonist, on wake after sleep onset (WASO).</p> <p><b>Methods:</b> Elderly (≥65 years) subjects (n = 58) with insomnia were randomly allocated (Latin square design) to receive five treatments (5, 10, 25, and 50 mg daridorexant and placebo) during five treatment periods, each consisting of two treatment nights followed by a 5–12-day washout period. Main efficacy endpoints were the absolute change from baseline in WASO (primary) and latency to persistent sleep (LPS; secondary) to Days 1&2 (mean of two treatment nights assessed by polysomnography) in each period. Safety and tolerability were also assessed.</p> <p><b>Results:</b> Of 58 subjects included, 67% were female and median age was 69 years [range 65–85]). WASO and LPS were dose-dependently reduced from baseline to Days 1&2 following daridorexant administration (multiple comparison procedure-modeling, p<0.0001 and p=0.004, respectively); reductions were statistically significant for doses 10 mg and above compared with placebo (WASO: –32.0, –45.1, –61.4 min; LPS: –44.9, –43.8, –45.4 min; for 10, 25, and 50 mg, respectively, p≤0.025). Treatment-emergent adverse events were similar for daridorexant and placebo; the most frequent were fatigue, nasopharyngitis, gait disturbance, and headache (≤7% in any group).</p> <p><b>Conclusions:</b> Daridorexant was well tolerated. Dose-dependent improvements in WASO and LPS were statistically significant (dose range 10–50 mg) in elderly subjects with insomnia disorder. ClinicalTrials.gov (NCT02841709).</p> <p><b>Classification of Evidence:</b> This study provides Class III evidence that for elderly subjects with insomnia, daridorexant reduced wake after sleep onset time.</p>
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.